midazolam has been researched along with s 1033 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ko, JH; Lin, W; Novick, S; Priess, P; Sheng, J; Zhang, H; Zheng, C; Zhou, W | 1 |
1 review(s) available for midazolam and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for midazolam and s 1033
| Article | Year |
|---|---|
Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2015 |